期刊文献+

地西他滨联合CAG方案治疗难治复发急性髓系白血病的疗效观察

下载PDF
导出
摘要 目的观察低剂量地西他滨联合CAG方案治疗难治复发急性髓系白血病(AML)的效果。方法 20例复发难治性AML患者给予地西他滨联合CAG方案治疗,观察患者的临床疗效及不良反应。结果 20例患者中完全缓解(CR)10例,部分缓解(PR)5例,病情稳定(SD)4例,进展(PD)1例,总有效率75%(15/20),1例患者出现Ⅰ度骨髓抑制,其余患者出现Ⅱ~Ⅲ度骨髓抑制;5例出现肺部感染,其中1例因重症感染死亡;1例出现腹痛明显。无黏膜炎发生,未见脱发。结论地西他滨联合CAG方案治疗难治复发AML疗效显著,不良反应可耐受,但由于观察病例较少,有待进一步研究。
出处 《中国实用医药》 2016年第29期152-153,共2页 China Practical Medicine
  • 相关文献

参考文献5

二级参考文献63

  • 1张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1.
  • 2Yamada K, Furusawa S, Saito K, etal. Concurrent use of granuloeyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia, 1995, 9: 10-14.
  • 3Ghoshal K, Bai S. DNA methyhransferases as targets for cancer therapy[J]. Drugs Today, 2007, 43: 395-422.
  • 4Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation[J]. N Engl J Med, 2003, 349: 2042-2054.
  • 5Issa JP, Gharibyan V, Cortes J. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate[J]. J Clin Oneol, 2005, 23: 3948-3956.
  • 6Chowdhury S, Sweopian S, Marks PW. Deeitabine combined with fraetionated gemtuzumab ozogamiein therapy in patients with relapsed or refractory acute myeloid leukemia[J]. Am J Hemaotol, 2009, 84: 599-600.
  • 7Scandura JM, Roboz G J, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML[J]. Blood, 2011, 118: 1472-1480.
  • 8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia [J]. Ann Hematol, 2012, 91: 1879-1886.
  • 9Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabinc and decitabine in combination in human leukemic cell lines [J]. Clin Cancer Res, 2007, 13: 4225-4232.
  • 10Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30(21 ):2670-2677.

共引文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部